Therapeutic delivery · 2018
Long-lasting immunosuppressive effects of tacrolimus-loaded micelle NK61060 in preclinical arthritis and colitis models.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sato Takamichi, Konno Junpei, Sekiguchi Akihiro, Yoneki Nao, Kawano Kana, Hayashi Tomohiro, Ogawa Yukina, Kikitsu Aya, Aijima Takashi, Hara Kazuhisa, Hara Shintaro, Hayashi Hitomi, Fuchigami Kimiko, Igo Naoko, Takashima Yuki, Kobayashi Yuki, Mori Masayuki, Yamamoto Keiichiro, Niwa Makoto, Saiga Kan, Ichimura Eiji
Аннотация
AIM: Tacrolimus (TAC) is an important drug for inflammatory diseases. However, TAC has several limitations, such as variable trough concentrations among individuals and a high medication frequency. In this study, we created NK61060, a novel micellar TAC formulation, to circumvent these disadvantages.
MATERIALS & METHODS: Immunosuppressive activity of NK61060 was determined in the collagen-induced arthritis rat model, mannan-induced arthritis mouse model and dextran sodium sulfate-induced colitis mouse model. The pharmacokinetics and toxicology of NK61060 were evaluated in those models.
RESULTS: In arthritis and colitis models, NK61060 exhibited superior immunosuppressive activity compared with that of TAC. Pharmacokinetic and toxicological analyses indicated that NK61060 had a wider safety margin and could be administered at a reduced medication frequency.
CONCLUSION: NK61060 mitigates the trough concentration variability and the medication frequency and it may be a safer and more effective option for use in clinical settings. Further studies are needed to determine its clinical usefulness.
MATERIALS & METHODS: Immunosuppressive activity of NK61060 was determined in the collagen-induced arthritis rat model, mannan-induced arthritis mouse model and dextran sodium sulfate-induced colitis mouse model. The pharmacokinetics and toxicology of NK61060 were evaluated in those models.
RESULTS: In arthritis and colitis models, NK61060 exhibited superior immunosuppressive activity compared with that of TAC. Pharmacokinetic and toxicological analyses indicated that NK61060 had a wider safety margin and could be administered at a reduced medication frequency.
CONCLUSION: NK61060 mitigates the trough concentration variability and the medication frequency and it may be a safer and more effective option for use in clinical settings. Further studies are needed to determine its clinical usefulness.
Предметные рубрики MeSH
AnimalsArea Under CurveArthritis, ExperimentalArthritis, RheumatoidColitis, UlcerativeCollagenDextran SulfateDrug Administration ScheduleDrug CarriersDrug Evaluation, PreclinicalFemaleHumansImmunosuppressive AgentsMannansMiceMice, Inbred ICRMicellesPolyethylene GlycolsRatsRats, Sprague-DawleyTacrolimus